Catalan researchers investigate whether a drug can prevent the development of covid in infected people. The study has the participation of 800 asymptomatic people and with a positive test. The drug, produced by the Grífols company, could be a breakthrough in the fight against the virus.
A clinical trial by the Foundation to Fight AIDS and Infectious Diseases evaluates the safety and efficacy of a drug developed by the pharmaceutical company Grífols .
The drug contains polyclonal anti-SARS-CoV-2 antibodies obtained from plasma donors who have overcome the disease and is based on an immunoglobulin that has previously been used for other conditions . This immunoglobulin from Grífols has already shown safety and efficacy in the prevention of various infectious diseases in immunocompromised patients.
It is expected that this medicine will prevent , in infected people, the appearance of symptoms , hospital admissions, that it is especially useful as a complement to the vaccine in the early phase after vaccination and that it can protect the elderly and health personnel , as well as in immunocompromised patients in whom vaccination is not recommended. The drug could also help contain outbreaks in places with a low vaccination rate.
For Oriol Mitjà “this treatment with immunoglobulins would provide a combination of polyclonal antibodies that, compared to monoclonal ones, present greater diversity and could improve the protection capacity against the virus “. Grífols’ medical director, Antonio Páez adds: “if its efficacy is confirmed, the new therapy could be administered to people who have tested positive for antigens and PCR in hospitals and primary care health networks.”
For Cristina Galvan, specialist at the University Hospital of Móstoles, “the patients included will receive very close attention and, if efficacy is confirmed, those who receive the product will have less risk of becoming ill or of presenting serious forms of covid-19 . If the results are positive, this treatment will be of great public health interest . “
The trial that began in mid-May in Catalonia, despite the fact that in April and with the collaboration of the Ministry of Health of the Community of Madrid, it has 800 asymptomatic individuals and with a positive diagnostic test for SARS-CoV-2 a those who are administered subcutaneously the immunoglobulin containing these antibodies against the virus . On the other hand, people already vaccinated or who have already passed the disease, will not be able to participate.